Th2 Suppression Through Antigen Liver Expression Using mRNA-LNP Technology

Area of Science:

• Immunology
• Gene Therapy
• Allergy Research

Background:

• Messenger RNA-lipid nanoparticle (mRNA-LNP) is an advanced nucleic acid delivery system.
• While mRNA vaccines are in clinical development, mRNA-LNP applications for allergies are under investigation.
• This study explores mRNA-LNP's potential to suppress immune responses in liver tissue for allergy treatment.

Purpose of the Study:

• To evaluate the efficacy of mRNA-LNP technology in suppressing immune responses related to allergies.
• To determine if expressing antigens in mouse liver tissue via mRNA-LNP can mitigate allergic inflammation.

Main Methods:

• Ovalbumin (OVA) antigen-expressing mRNA was synthesized and encapsulated into LNPs (OVA-mRNA-LNP).
• The OVA-mRNA-LNP was tested in an OVA-sensitized mouse model, assessing splenocyte cytokine production and regulatory T cell (Treg) populations ex vivo.
• Prophylactic and therapeutic administration of OVA-mRNA-LNP was evaluated in an OVA-induced airway inflammation model.

Main Results:

• OVA-mRNA-LNP administration led to suppressed Th2 cytokines (IL-4, IL-5) and increased Treg populations in stimulated splenocytes.
• Significant reduction (40-80%) in Th2 cytokines was observed in Bronchoalveolar Lavage Fluid (BALF) following both prophylactic and therapeutic OVA-mRNA-LNP treatment.
• These findings indicate successful modulation of the immune response against the allergen.

Conclusions:

• Messenger RNA-lipid nanoparticle technology represents a safe, non-viral gene delivery method.
• Antigen expression in liver tissue using mRNA-LNP is a viable strategy for suppressing allergen-induced inflammation.
• This approach holds promise for managing allergic diseases.